CADL
Candel Therapeutics Inc
11.60$
+2.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -16.7% | -25.1% | -15.2% | -18.8% | +396.7% | -10.3% | +10.5% | -11.7% | +33.8% | +61.3% | +3.1% | |
| – | -18.4% | -26.3% | -16.2% | -20.5% | +474.0% | -10.3% | +11.2% | -13.0% | +32.8% | +65.2% | +3.2% | |
| – | -17.6% | -27.4% | -16.6% | -22.8% | +520.0% | -10.2% | +9.2% | -13.6% | +37.7% | +62.7% | +3.5% | |
| – | -17.6% | -27.4% | -16.6% | -22.8% | +520.0% | -10.2% | +9.2% | -13.6% | +37.7% | +62.7% | +3.5% | |
| – | +7.1% | -12.8% | +44.5% | +0.9% | +10.2% | -47.6% | -25.8% | -14.5% | +443.8% | -12.8% | +28.4% | |
| – | +37.3% | -4.6% | +3.4% | +9.1% | +145.8% | -46.5% | -26.7% | -25.7% | -17.7% | -21.6% | +79.9% | |
| – | +42.5% | +9.4% | +5.8% | +0.6% | -4.5% | -6.8% | -25.2% | -36.1% | -90.5% | +1.8% | +1.8% | |
| – | +68.8% | +11.8% | -8.3% | -31.6% | -19.9% | +220.7% | +157.0% | -42.8% | +1.0% | +168.9% | +69.8% | |
| – | -17.8% | -19.6% | -24.5% | -32.6% | -48.6% | -65.3% | +3.9% | +3.6% | +4,743.8% | +0.7% | +0.7% | |
| – | -44.6% | -53.1% | -266.8% | – | – | +12.6% | +20.8% | -11.2% | -35.2% | +165.8% | -8.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.7% | +2.3% | +7.1% | +11.1% | -10.9% | +62.6% | +6.6% | +0.0% | +13.6% | +18.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.